Article Text

Download PDFPDF

2022-RA-1441-ESGO Epithelial ovarian cancers during pregnancy: the results of a large retrospective study from the INCIP network
  1. Robert Fruscio1,
  2. Rita Trozzi2,
  3. Kristel van Calsteren3,
  4. Martina Delle Marchette1,
  5. Anna Fagotti2,
  6. Floriana Mascilini2,
  7. Elyce Cardonick4,
  8. Michael J Halaska5,
  9. Christine AR Lok6,
  10. Juliane Farthmann7,
  11. Nelleke Ottevanger8,
  12. Stefania Galimberti1,
  13. Joosje H Heimovaara9 and
  14. Frédéric Amant10
  1. 1Department of Medicine and Surgery, Università Degli Studi Milano-Bicocca, San Gerardo Hospital, Monza, Italy
  2. 2Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
  3. 3Department of Obstetrics and Gynecology, University Hospitals Leuven, and Department of Development and Regeneration, KU Leuven, Leuven, Belgium
  4. 4Department of Obstetrics and Gynecology, Cooper University Health Care, Camden, NJ
  5. 53rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
  6. 6Department of Gynecologic Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
  7. 7Comprehensive Cancer Center Freiburg (CCCF); Department of Obstetrics and Gynecology, University Medical Center, Faculty of Medicine, Freiburg im Breisgau, Germany
  8. 8Department of Medical Oncology, Radboudumc, Nijmegen, Netherlands
  9. 9Department of Oncology, KU Leuven, Leuven, Belgium; Department of Gynecology, Antoni van Leeuwenhoek, Amsterdam, Netherlands
  10. 10Department of Oncology, KU Leuven, Leuven, Belgium; Department of Gynecology, Antoni van Leeuwenhoek – Netherlands Cancer Institute; Center for Gynecological Oncology Amsterdam (CGOA), Antoni van Leeuwenhoek – Netherlands Cancer Institute, Amsterdam, Netherlands


Introduction/Background The malignancy rate of adnexal masses in pregnancy is 0.2–3.8/100.000 cases. Even though malignant ovarian cancer diagnoses in pregnancy are uncommon, awareness is crucial to obtain an adequate oncological treatment and a good obstetrical outcome.

Methodology Using the INCIP (International Network on Cancer, Infertility and Pregnancy) registry, we describe the characteristics and the outcomes of a series of patients affected by borderline ovarian tumors (BOT) and invasive epithelial ovarian cancers (EOC).

Results 129 patients were included, 69 (53%) affected by BOT and 60 (47%) by EOC. The majority of patients (74%) diagnosed in the first trimester of pregnancy were treated with surgery ± chemotherapy. During the second trimester, 22 patients received surgery and 16 surgery + chemotherapy. In the third trimester, only two patients were treated with surgery because of severe symptomatic diseases. No major surgical or chemotherapy-related adverse events were reported. The median gestational age at the delivery was 39, three patients had a preterm delivery due to oncological reasons. Birthweight was significantly lower in women treated with chemotherapy (mean 2528 grams vs 3031, p: 0.01). 20 patients with BOT relapsed and two of them died (one relapsed as low-grade serous carcinoma and one as a mucinous carcinoma). Among patients with EOC, the relapse rate was 25% and mortality was 18%. In two patients a benign disease was suspected, and they were not treated during pregnancy. Unfortunately, they relapsed and subsequently died.

Conclusion Treatment of ovarian tumors is feasible during pregnancy and obstetrical outcomes are satisfactory. Both surgery and chemotherapy appear to be safe and effective. When chemotherapy is administered during pregnancy, fetal growth should be carefully monitored. Further research is needed to enlighten the possible influence of pregnancy on the oncological outcome of ovarian cancer patients.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.